All
Harmonized Lifecycle Management Policy Aims to Drive Drug Quality and Innovation
May 26th 2021FDA recently published a final guidance for making post-approval manufacturing changes to drugs and biologics, the culmination of a long-running effort to facilitate improvements in medical product quality through the product life cycle.
Moderna and Samsung Biologics Partner on Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
May 24th 2021Samsung Biologics plans to support the production of hundreds of millions of doses of Moderna’s vaccine to supply to markets outside of the United States beginning in the third quarter of 2021.
bluebird bio’s One-Time Gene Therapy for CALD Receives Positive Opinion from CHMP
May 24th 2021The Committee for Medicinal Products for Human Use of the European Medicines Agency presented a positive opinion of bluebird bio’s SKYSONA (elivaldogene autotemcel, Lenti-D), a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy, an X-linked metabolic disorder.
FDA Publishes Guidance on Biopharmaceutics Classification System-Based Biowaivers
May 20th 2021The guidance document gives recommendations to support biopharmaceutics classification of drug substances and the Biopharmaceutics Classification System-based waiver of the in-vivo bioequivalence study requirement for drugs.
Pfizer and BioNTech to Supply EU with Up to 1.8 Billion Additional COVID-19 Vaccine Doses
May 20th 2021Pfizer and BioNTech have entered into a new agreement with the European Commission to supply 900 million doses of Comirnaty to the European Union with an option to request up to 900 million additional doses.
Bristol Myers Squibb Enters into Agreement with Agenus for Up to $1.56 Billion
May 19th 2021Bristol Myers Squibb has entered into a definitive agreement with Agenus for a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.